EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6C1: CytomX Therapeutics Inc

18 Nov 2025
LAST:

3.030

CHANGE:
 0.06		OPEN:
3.030		HIGH:
3.030		ASK:
0.000		VOLUME:
1.8K
CHG(%):
1.88		PREV:
3.088		LOW:
3.030		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
18 Nov 253.0303.0303.0303.0301.8K
17 Nov 253.2723.2723.0883.0881.8K
14 Nov 253.2483.2483.2483.2481.4K
13 Nov 253.5883.5883.4263.4261.4K
12 Nov 253.4783.4783.4783.4781.4K
11 Nov 253.5583.5583.4483.4481.4K
10 Nov 253.1383.1383.1383.1381.0K
07 Nov 253.4003.4003.4003.4001.0K
06 Nov 253.6123.8003.6123.8001.0K
05 Nov 253.4303.8223.4303.8004.0K

PROFILE

Name:CytomX Therapeutics Inc
About:CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.cytomx.com
ISIN:US23284F1057
LEI:5493004VW2FW0QLL3345

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:7.86 
Forward P/E:-2.19 
PEG Ratio:-0.08 
Price to Sales:3.95 
Price to Book:4.65 
Profit Margin:0.34 
Operating Margin:-0.07 
Return on Assets:0.16 
Return on Equity:1.08 
Revenue:122.46M 
EBITDA:23.23M 
Shares:164.91M 
Market Cap:499.69M 

TECHNICAL INDICATORS

MA5:3.257.4%
MA10:3.3911.7%
MA20:3.164.3%
MA50:2.6713.5%
MA100:2.2733.5%
MA200:1.7177.7%
STO14:25.00
RSI14:55.27
WPR14:-74.47
MTM14:0.26
ROC14:0.10 
ATR:0.21 
Week High:3.5918.4%
Week Low:3.030.0%
Month High:3.8226.1%
Month Low:2.6877.7%
Year High:3.8226.1%
Year Low:0.38695.3%
Volatility:17.14